Presented to the Board or a committee
Vaurenne Therapeutics
Board
September 2017 — present
Present corporate portfolio choices and their commercial dependencies as CSO. This is executive presentation exposure, with no statutory directorship.
Raphael Laurier · Chief Strategy Officer · Canada
I would help the board hear the dependency behind the proposed breadth.
Committee contribution
| Capacity | Committees |
|---|---|
| Ready to join | A strategy or portfolio committee that needs commercial-dependency experience alongside specialist pharmaceutical knowledge |
Capacity and preferences
- Time available
- 24 days per year
- Current directorships
- 0
- Sectors
- Established medicines · Healthcare businesses assessing portfolio concentration · Companies reviewing the support needs of mature activities
- Company type
- An established private healthcare business with distinct scientific, operating and corporate decision authorities
- Company stage
- A company testing whether acquisition, expansion or portfolio changes provide the breadth it intends
The seat I am pursuing
I would consider a first non-executive role in an established healthcare business whose portfolio choices need commercial-dependency scrutiny alongside strong scientific and operating expertise. A strategy or portfolio committee could be relevant if its mandate matched that contribution. My record does not establish competence to chair a medical, audit, risk or other specialist committee, and I would not present executive experience as a substitute for the preparation the actual appointment requires.
There are no statutory directorships in this chronology. Board presentations since September 2017 and a former engagement-director title are stated on their executive and employment bases. I would want a search discussion to preserve those distinctions while considering what I could add. The intended next step is a responsibly assessed first seat, with the institution's needs taking precedence over the appeal of a title. Every organisation and outcome here is fictional, so a real appointment would require verified evidence and its own suitability assessment.
Board and committee exposure
Governance learning and readiness
IICA Independent Directors’ Databank: Not yet registered
No completed Indian independent-director databank registration is included here. If considering an Indian appointment, I would examine current requirements and preparation for that particular situation; the fictional international career implies no exemption.
- I would prepare to scrutinise a management proposal collectively rather than defend it as its executive author.
- Induction should cover the company’s pharmaceutical responsibilities and how qualified specialists report their evidence to the board.
- I would seek a clear understanding of the financial, governance and jurisdictional duties attached to the actual seat.
My contribution to a board
I could help a board examine whether a proposed portfolio change alters the dependence that matters to its decision. A new category, geography or activity can be strategically valuable without providing all the diversification suggested by its presentation. My contribution would be to ask which relationship has changed, which remains shared and why the remaining concentration is acceptable. That question should make management's reasoning more assessable without turning commercial familiarity into authority over the scientific or medical evidence.
The proposed acquisition portfolio with forty-five per cent exposure to a familiar purchasing group is one example. I would want the board to hear the corporate development argument for the new therapeutic areas as well as the concentration concern. The case should not become a competition between ambition and caution in which one side is automatically responsible. The question is what the transaction offers on its actual terms, including a dependency it does not remove. A board may choose to accept that dependence, but it should understand the reason.
I would also bring the memory of my own nine-brand error. A persuasive classification can become part of the institution's accepted account before someone examines the connection beneath it. On a board, that experience would make me attentive to a colleague who questions a familiar category, including one I initially support. It would not make my interpretation final. I would need the scientific, medical, commercial and financial expertise around the table to understand which distinctions have practical significance for the company in front of us.
Judgement in practice
Ask what a broader map leaves commercially connected
The two-market proposal placed 56% of its modelled annual sales through one distribution group. In a board discussion I would ask management to show the benefit of that route alongside the concentration, then explain the commitment being sought. I would keep the C$135 million estimate on its prospective basis and seek the responsible owners’ conclusions on the requirements for the actual business. The selected one-market preparation carried C$2.4 million expense and gave up simultaneous momentum. Those qualifications matter because the case does not establish that geographical expansion is wrong or that sequential preparation always reduces exposure.
Keep early possibilities and established activities distinct
The fourteen-initiative account placed nine early development activities beside five established-medicine extensions. I would ask how the board can see the evidence and uncertainty appropriate to each group before using a total count. The earlier activities may be strategically important even though they cannot support the same conclusions as established work. I would seek specialist interpretation and avoid supplying clinical probabilities or valuation assumptions from my own commercial experience. The purpose would be an intelligible collective discussion of the portfolio, with its ambition intact and its maturity differences visible, rather than a single measure that invites an unsupported comparison.
Do not let a possible exit erase the current undertaking
The smaller portfolio’s C$26 million annual revenue and C$4.2 million support estimate describe different aspects of the business and do not form a complete margin account. I would ask how management is planning for the work that continues while long-term options are examined. The board would need the relevant professional and operating owners’ assessment, not a strategist’s assurance that a smaller activity can be treated as residual. My experience would help identify the gap between considering a change and having completed it. The decision could still include disposal, provided the present undertaking remains part of the account.
My first year on a board
I would begin by learning how the company defines its portfolio and which decisions the board is being asked to make about it. The same therapeutic or business label can conceal very different commercial and professional contexts. I would want to understand the institution's own categories before importing comparisons from Vaurenne. Induction with the scientific, medical, quality, safety, regulatory, operating and finance leaders would help me recognise where a commercial question depends on specialist evidence I am not qualified to supply.
I would examine how the board receives an account of shared buyers, channels and other dependencies, and how that account changes when a transaction or expansion is proposed. I would also ask how early activities and established work are distinguished in the strategic material. The aim would be to identify useful questions for management and the chair, rather than request a new presentation simply because it resembles one I have used before.
My initial twenty-four-day annual estimate would include preparation and committee work and would remain conditional on employer agreement and the actual demands. Exceptional events could require substantially more attention. I would review whether the commitment remained realistic and whether my contribution complemented the board's capabilities. If the role needed competence or capacity I could not provide, I would raise that early rather than rely on the initial estimate as if it settled the matter.
Conflicts and their management
An appointment could intersect with my employer's acquisition interests, purchasing relationships, distribution arrangements or other commercial connections. I would disclose the relevant facts and seek the institution's assessment and appropriate advice. Some relationships might prevent useful participation or make the seat unsuitable; identifying them would not automatically resolve the conflict. The review would also need to consider connections that developed after appointment, including a proposed transaction that changed the relationship between the organisations.
I would keep confidential product, transaction and counterpart material within its authorised setting. A public biography should not imply that executive access is personal evidence available for another company's use. My contribution would need to rest on permitted experience and the materials properly available to that board. This demonstration contains invented examples, but a real candidate would need a careful review of publication permissions and any restrictions affecting the contemplated role.
My independence statement
I would provide the appointing institution with the employment, transaction, purchasing and personal connections relevant to its assessment. A separate company name would not by itself establish independence. Employer permission, appropriate advice and the actual relationships would need review before acceptance.